Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 17:51 ET | Source: Bragar Eagel & Squire

SIMPLY GOOD FOODS ALERT: Bragar Eagel & Squire, P.C. is Investigating The Simply Good Foods Company on Behalf of Simply Good Foods Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Simply Good Foods (SMPL) To Contact Him Directly To Discuss Their Options If you...
April 22, 2026 17:50 ET | Source: Bragar Eagel & Squire

ONEMAIN INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating OneMain Holdings, Inc. on Behalf of OneMain Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In OneMain (OMF) To Contact Him Directly To Discuss Their Options If you purchased or...
April 22, 2026 17:48 ET | Source: Bragar Eagel & Squire

VERITONE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Veritone, Inc. on Behalf of Veritone Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Veritone (VERI) To Contact Him Directly To Discuss Their Options If you purchased or...
April 22, 2026 17:30 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée ...
April 22, 2026 17:30 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with...
April 22, 2026 17:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...
April 22, 2026 17:22 ET | Source: United Negro College Fund, Inc. (UNCF)

UNCF Mourns the Passing of Congressman David Scott

WASHINGTON, DC, April 22, 2026 (GLOBE NEWSWIRE) -- UNCF joins the nation in mourning the passing of U.S. Representative David Scott (D-GA-13), a steadfast champion for Historically Black Colleges...
April 22, 2026 17:15 ET | Source: Home BancShares, Inc.

Home BancShares, Inc. Announces Second Quarter Dividend

CONWAY, Ark., April 22, 2026 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced that its Board of Directors has declared a regular $0.21 per...
April 22, 2026 17:15 ET | Source: Canfor Corporation

Canfor releases 2025 Sustainability Report

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Canfor Corporation (TSX: CFP) released its 2025 Sustainability Report today. The report provides an overview of the company’s...
April 22, 2026 17:13 ET | Source: StorageVault Canada Inc.

StorageVault’s Disciplined Operational Execution Delivers Strong Same Store Growth and AFFO Gains in Q1 2026; Increases Dividend

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX) reports the Corporation’s Q1 2026 results. Iqbal Khan, Chief Financial Officer,...